Verastem, Inc. (VSTM) Balance Sheet

The oscillation between positive and negative equity suggests that the company's capital structure is highly sensitive to the timing of financing rounds and the intensity of clinical trial expenditures. Investors should monitor whether the current equity base can remain stable as the RAMP clinical programs continue to consume resources without a corresponding commercial revenue stream.

The doubling of debt levels over the observed period suggests that management is increasingly utilizing leverage to bridge the gap between clinical development costs and milestone-based inflows. This trend warrants caution, as higher interest obligations may further constrain cash flow durability if clinical milestones are delayed or fail to materialize.

While the current ratio appears healthy on the surface, it is heavily dependent on the cash balance rather than operational working capital efficiency. The liquidity profile suggests that the company is well-positioned for the near term, but the lack of recurring revenue means this buffer is finite and subject to rapid depletion.